minor | intermediate | severe | P value | |
---|---|---|---|---|
n = 50 | n = 274 | n = 314 | ||
Gender (male, %) | 43 (86.0) | 226 (82.5) | 269 (85.7) | 0.538 |
Age, y | 50.00 [40.25, 60.50] | 50.00 [45.00, 58.75] | 51.00 [45.00, 60.00] | 0.642 |
AFP (> 400 ng/mL, %) | 16 (32.0) | 112 (40.9) | 134 (42.7) | 0.361 |
HBeAg (%) | 13 (26.0) | 41 (15.0) | 80 (25.5) | 0.005 |
Tumor size, cm | 4.85 [3.00, 7.32] | 4.05 [3.00, 7.50] | 4.50 [3.00, 6.80] | 0.995 |
Multiple tumor (%) | 1 (2.0) | 2 (0.7) | 9 (2.9) | 0.163 |
Poorly differentiation, (%) | 25 (50.0) | 124 (45.3) | 151 (48.1) | 0.717 |
Hepatic fibrosis | < 0.001 | |||
minor | 18 (36.0) | 84 (30.7) | 23 (7.3) | |
advanced | 12 (24.0) | 62 (22.6) | 76 (24.2) | |
cirrhosis | 20 (40.0) | 128 (46.7) | 215 (68.5) | |
MVI, (%) | 8 (16.0) | 69 (25.2) | 92 (29.3) | 0.114 |
Satellite, (%) | 2 (4.0) | 21 (7.7) | 37 (11.8) | 0.092 |
Fatty liver, (%) | 12 (24.0) | 52 (19.0) | 80 (25.5) | 0.165 |
Capsule invasion, (%) | 26 (52.0) | 124 (45.3) | 118 (37.6) | 0.056 |
HBV-DNA, (> 2000 IU/mL, %) | 19 (38.0) | 130 (47.4) | 190 (60.5) | 0.001 |
PT, s | 12.10 [11.70, 12.50] | 12.10 [11.50, 12.90] | 12.10 [11.60, 12.88] | 0.881 |
INR | 1.00 [1.00, 1.10] | 1.00 [1.00, 1.10] | 1.00 [1.00, 1.10] | 0.773 |
RBC, x109/L | 4.65 [4.26, 5.16] | 4.74 [4.30, 5.04] | 4.73 [4.35, 5.10] | 0.661 |
HB, g/L | 144.50 [125.50, 154.00] | 145.00 [132.00, 155.00] | 147.00 [136.00, 155.75] | 0.127 |
PLR(> 101, %) | 14 (28.0) | 122 (44.5) | 110 (35.0) | 0.017 |
NLR(> 2.6, %) | 15 (30.0) | 94 (34.3) | 95 (30.3) | 0.548 |
ALT(> 40 IU/L, %) | 16 (32.0) | 100 (36.5) | 146 (46.5) | 0.019 |
AST(> 40 IU/L, %) | 21 (42.0) | 92 (33.6) | 132 (42.0) | 0.094 |
ALB(≤ 40 g/L, %) | 1 (2.0) | 7 (2.6) | 14 (4.5) | 0.38 |
TBIL(> 28 umol/L, %) | 2 (4.0) | 5 (1.8) | 12 (3.8) | 0.33 |
PLT(≤ 100 × 109/L, %) | 17 (34.0) | 66 (24.1) | 107 (34.1) | 0.024 |
FIB-4(> 3.6, %) | 17 (34.0) | 66 (24.1) | 97 (30.9) | 0.12 |